The Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the COVID-19 pandemicThe SARS-CoV-2 Omicron variant is rapidy spreading worldwide and a public health concern. Experiments show that this variant resistant against several therapeutic antibodies for COVID-19 and efficiently evades antibodies induced upon infection or double BNT162b2 vaccination, however not triple BNT162b2 or ChAdOx1/BNT162b2 vaccination.The SARS-CoV-2 Omicron variant is rapidy spreading worldwide and a public health concern. Experiments show that this variant resistant against several therapeutic antibodies for COVID-19 and efficiently evades antibodies induced upon infection or double BNT162b2 vaccination, however not triple BNT162b2 or ChAdOx1/BNT162b2 vaccination.Markus Hoffmann, Nadine Krüger, Sebastian Schulz, Anne Cossmann, Cheila Rocha, Amy Kempf, Inga Nehlmeier, Luise Graichen, Anna-Sophie Moldenhauer, Martin S. Winkler, Martin Lier, Alexandra Dopfer-Jablonka, Hans-Martin Jäck, Georg M.N. Behrens, Stefan Pöhlmannhttps://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2821%2901495-1%3Frss%3Dyes&rc=0http://www.cell.com/cell/inpress.rssCellCell RSS feed.Wireless News CampaignDecember 24, 2021

Powered by WPeMatico